Fusen Pharmaceutical Co., Ltd. (HK:1652) has released an update.
Fusen Pharmaceutical Co., Ltd. has announced the approval of a clinical trial for its innovative traditional Chinese medicine, SY617, by China’s National Medical Products Administration. SY617 is designed to treat influenza with symptoms of wind-heat and dampness syndrome, and its market potential is underscored by the substantial sales of traditional Chinese cold medicines. This product is expected to offer a new treatment option for flu patients and signifies a significant addition to Fusen Pharmaceutical’s anti-flu medicine portfolio.
For further insights into HK:1652 stock, check out TipRanks’ Stock Analysis page.